VintaBio

Cambridge, MA
AAV Lentiviral
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
59.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: VintaBio

Signal Score
59.0/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
Cambridge, MA
Modalities
AAV, Lentiviral
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About VintaBio

Early-stage CGT CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 manufacturing site: Cambridge, MA
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Cambridge, MA
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Cambridge, MA
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100

FDA 483 Findings 2 observations · 2025-10-22 → 2025-10-22 ?

By subsystem

  • Documentation & Records 1 (50.0%)
  • CAPA 1 (50.0%)

By severity

  • 3 — Moderate: 1
  • 2 — Minor: 1
  • Repeat observations: 0

Most severe findings

  • Moderate (3) CAPA 2025-10-22 21 CFR 111.503
    Written procedures - establish; returned dietary supplements

    "You did not establish written procedures for when a returned dietary supplement must be destroyed, or otherwise suitably disposed, when a returned dietary supplement may be salvaged and for conducting an investigation of your manufacturing processes and other batches for a returned dietary supplement."

  • Minor (2) Documentation & Records 2025-10-22 21 CFR 111.453
    Written procedures - establish; holding and distribution

    "You did not establish written procedures for holding and distributing operations."

About this data →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs →

Similar CDMOs

Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.1
AAV, Lentiviral, Plasmid DNA, Adenoviral
Genezen
Indianapolis, IN · Lexington, MA
Signal Score: 70.7
AAV, Lentiviral
uBriGene Biosciences
Shanghai, CN · Boston, MA
Signal Score: 60.5
AAV, Lentiviral, Plasmid
ElevateBio BaseCamp
Waltham, MA
Signal Score: 59.0
AAV, Lentiviral, CAR-T
Vector BioMed
Cambridge, MA
Signal Score: 59.0
AAV, Lentiviral